A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Research Roundup: Clinical trial data sharing, vaccines to look forward to, and public-private partnerships for global health research and development

Read time:
PATH/Will Boase

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

January 20, 2015 by Kat Kelley

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Johnson & Johnson announced that it will share detailed information on its clinical trials through Yale University’s Open Data Access Project. This will include data on all Johnson & Johnson medical devices, diagnostics, and drugs approved since the beginning of 2014. "An open data movement is really gaining momentum," according to Dr. Victor Dzau, president of the Institute of Medicine, however "we need to develop a culture that supports data sharing, and we need to provide incentives and develop trust." The European Medicines Agency, which regulates drug approvals in Europe, is also contributing to the open data movement, and plans to publish detailed data for all new drugs approved by the agency.

The Japan Times took an in-depth look at the Global Health Innovation Technology Fund (GHIT), a Tokyo-based member of the Global Health Technologies Coalition and a partnership between the Japanese government, five major pharmaceutical companies, the Bill & Melinda Gates Foundation, and the United Nations Development Program. GHIT seeks to promote the research and development of treatments for infectious diseases by subsidizing the costs for biotech companies and facilitating partnerships between the private and public sector. The Fund has contributed to the development of 30 drugs since its establishment in 2013, including several neglected tropical diseases such as leishmaniasis, schistosomiasis, and dengue fever.

The ONE blog identified five major, deadly diseases for which vaccines are currently being developed. The blog highlights challenges to development and provides updates on leading vaccine candidates for HIV and AIDS, Malaria, Tuberculosis, Ebola, and cancers, including liver cancer caused by hepatitis C.

Categories: Research Roundup, Vaccines

About the author

Kat KelleyGHTC

Kat Kelly is a senior program assistant at GHTC who supports GHTC's communications and member engagement activities.

Other Breakthroughs Blog posts you may like:
White House/Pete Souza
January 20, 2015

Obama highlights global health and innovation in State of the Union address

Written by Marissa Chmiola / GHTC
Read time:
President Obama discussed global health and innovation in the 2015 State of the Union address. Photo: Official White House Photo by Pete Souza While others were playing State of the Union bingo or creating pretty word clouds, GHTC was closely watching the State of the Union address to see what President Barack Obama would say about US engagement in global health and America’s leadership in science and innovation. GHTC was glad to see the President highlight American involvement in combatting Ebola and underscore the need for a more effective global effort to address future health crises. Obama said: “In West Africa, our troops, our scientists, our doctors, our nurses and healthcare workers are rolling back Ebola — saving countless lives and stopping the spread of disease. I couldn’t be prouder of them, and I thank this Congress for your bipartisan support of their efforts. But the job is not yet done — and the world needs to use this lesson to build a more effective global effort to prevent the spread of future pandemics, invest in smart development, and eradicate extreme poverty.” The President also emphasized how American investments in research and innovation have saved lives and contributed to the economy. He said: “21st century businesses will rely on American science, technology, research, and development. I want the country that eliminated polio and mapped the human genome to lead a new era of medicine — one that delivers the right treatment at the right time.” GHTC was pleased to see America’s Commander-in-Chief draw attention to the US role in advancing innovation to save lives. For more information on why US policymakers should invest in global health research and development, check out our recent blog post, “10 reasons why US policymakers should support global health research and development.”
PATH/Gabe Bienczycki
January 12, 2015

Research Roundup: MenAfriVac® prequalification, an innovative new antibiotic, Ebola vaccine trials, and more

Written by Kat Kelley / GHTC
Read time:
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. Kathy Neuzil, director of Vaccine Access and Delivery at PATH, reflects on the lessons learned from Meningitis Vaccine Project (MVP) in light of the achievement of its final milestone: World Health Organization prequalification of an infant version of the meningitis A MenAfriVac® vaccine. MenAfriVac® was approved for people aged 1 to 29 years in 2010, and has since been used to effectively protect 215 million people in sub-Saharan Africa. Neuzil attributes MVP’s success to the tenacity of its team and the inclusion of country partners at every stage from product development to distribution. A new type of antibiotic may be the key to treating drug-resistant infections, according to a study published in Nature last week. The antibiotic, teixobactin, was extracted from dirt, and fights infections by targeting the fatty molecules that bacteria use to build their cell walls. While most antibiotics target the bacteria’s DNA, which can be easily mutated, the study’s lead researcher, Kim Lewis, believes it would take at least 30 years for the fatty molecules to mutate and thus develop resistance to teixobactin. The antibiotic has been successfully tested on mice with no side effects, and could be available for use in humans in five to six years. Johnson & Johnson has started human trials of an experimental Ebola vaccine in the United Kingdom, and hopes to expand testing to approximately 2,000 people by mid-February. Johnson & Johnson has produced over 400,000 courses of the vaccine and has invested significantly in the Danish pharmaceutical company Bavarian Nordic to develop a booster shot to enhance the efficacy of the vaccine and to promote long-term protection against Ebola. Dr. Margaret Hamburg, commissioner of the Food and Drug Administration (FDA), sat down with Ryan Hohman of Friends of Cancer Research last week to discuss hot topics in FDA drug policy. Hamburg affirmed the FDA’s commitment to expediting research and development of new treatments, stating that in this “critical time for biomedical research and innovation” the FDA has a role to play in “translating all of the exciting new discoveries and opportunities and science into real world products that matter for people.”